Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to -$1.4 billion.

  • Syndax Pharmaceuticals' Retained Earnings fell 2764.69% to -$1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 billion, marking a year-over-year decrease of 2764.69%. This contributed to the annual value of -$1.2 billion for FY2024, which is 3532.34% down from last year.
  • Syndax Pharmaceuticals' Retained Earnings amounted to -$1.4 billion in Q3 2025, which was down 2764.69% from -$1.4 billion recorded in Q2 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Retained Earnings registered a high of -$543.7 million during Q4 2021, and its lowest value of -$1.4 billion during Q3 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' median Retained Earnings value was -$778.8 million (recorded in 2023), while the average stood at -$877.8 million.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Retained Earnings skyrocketed by 438.35% in 2021, and later tumbled by 3579.38% in 2024.
  • Syndax Pharmaceuticals' Retained Earnings (Quarter) stood at -$543.7 million in 2021, then fell by 27.47% to -$693.0 million in 2022, then plummeted by 30.21% to -$902.4 million in 2023, then plummeted by 35.32% to -$1.2 billion in 2024, then dropped by 17.8% to -$1.4 billion in 2025.
  • Its Retained Earnings stands at -$1.4 billion for Q3 2025, versus -$1.4 billion for Q2 2025 and -$1.3 billion for Q1 2025.